LD-2 disclosure · 4th Quarter - Termination
CELGENE CORPORATION
Expenses$400Kself-filed spend
Client
- Location
- New Jersey · United States of America
Registrant
- Description
- 8/1/2004
- Location
- Summit, New Jersey, United States of America
Lobbying activities
1 issueHealth Issues
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279 / S.2546, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
LobbyistsGREG CHESMORE · STEPHEN RUBRIGHT · ALANNA TEMME
TargetedSENATE · HOUSE OF REPRESENTATIVES